Pharma Pulse 8/13/24: How Should Biotechs Strategize for 2025, Pfizer Announces Top-Line Results of ABRYSVO for RSV & more

How Should Biotechs Strategize for 2025

As the biotech industry looks toward 2025, companies must navigate a complex landscape marked by regulatory challenges, evolving funding trends, and technological advancements. Their strategies will drive innovation, ensure sustainability, and maintain competitiveness.

Study Finds Increased Risk of Mental Health Disorders Following Cardiovascular Hospitalization

A study published in the Journal of the American Heart Association (AHA) indicated that individuals who were hospitalized after a cardiac event, including heart disease, stroke, and other cardiovascular diseases (CVD), were 83% more likely to be diagnosed with anxiety or depression.

Trump Campaign Says It Was Hacked

GOP campaign alleges Iran could be responsible, saying documents were stolen by ‘foreign sources’.

Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults

Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating two doses of ABRYSVO vaccine in immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).

Judi by AG Mednet, Inc. on LinkedIn

Applied Clinical Trials Magazine reports on advances in the fight against #MultipleMyeloma. Recently, Judi by AG Mednet supported a clinical-stage biotech's Multiple Myeloma trial, combining Judi for Eligibility and Judi for Adjudication. Learn more on our Insights page. Judi.io

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs